Pocket Psych Drugs: Point-of-Care Clinical Guide

Pedersen, Darlene D. MSN, APRN

Other formats:

Book Information
Edition:	1st
Publisher:	Davis, F.A.
ISBN:	0-8036-2201-5 (0803622015)
ISBN-13:	978-0-8036-2201-2 (9780803622012)
New Edition:	0-8036-7578-X
Format:	Handbook/Pocketbook
Binding:	Softcover
Copyright:	2010
Publish Date:	09/09
Bookstore Series:	Davis's Notes Series (See all titles)
Weight:	0.36 Lbs.
Pages:	205
Carton Quantity:	80
Subject Class:	NPM (Nursing Pharmacology)
Remarks:	A New Edition of this Title is Available
Return Policy:	Returns accepted up to 10 months provided no other recalls or return restrictions apply.
Table Of Contents:	View
Contributing Authors:	View
ProQuest Ebook Central:	Available in ProQuest Ebook Central™ View

Class Specifications
Discipline:	Nursing
Subject Definition:	Mental Disorders-Nsg-Hndbks; Psychotropic Drug-Therapeut Use
NLM Class:	WY 49
LC Class:	RC440
Abstract:	In this title, more than 70 drug monographs provide targeted pharmacologic information on indications, pharmacokinetics, dosages, adverse reactions, and drug interactions, including herbal and food interactions. Special features address considerations for special populations. Detailed assessments tell you what needs to be monitored when administering a specific drug. Available dosage forms provide costs for selected drugs. There are monographs, organized alphabetically by generic name, detailing geriatric, pediatric, and substance abuse considerations, as well as clinical assessments and clinical alerts highlighting essential patient safety information for the clinician at 'point-of-care'. This title provides coverage of psychopharmacology and psychobiology, including pharmacodynamics, pharmacokinetics, drug-herbal interactions, therapeutic drug classes, and side effects associated with specific classes; common and therapeutic lab values, as well as clozaril protocol; Tools Tab featuring common abbreviations, medication assessment tool, psychotropic approximate dose equivalencies, pregnancy categories, controlled substances schedules, BMI and metabolic syndrome, and conversion of trade to generic names; and, FDA-approved 'Black Box Warnings' highlighting serious risks and precautions.